 VICTORIA, British Columbia ROCKVILLE, Md.--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH TSX: AUP Aurinia or the Company today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association European Dialysis and Transplant Association ERA-EDTA 2021 Congress. The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology EULAR 